DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients

Jieting Tang1,2 · Huarong Chen1 · Chi-Chun Wong1 · Dabin Liu1 · Tong Li1 · Xiaohong Wang3 · Jiafu Ji3 · Joseph JY Sung1 · Jing-Yuan Fang2 · Jun Yu1,2

Received: 26 October 2017 / Revised: 16 January 2018 / Accepted: 3 February 2018 / Published online: 14 March 2018
© The Author(s) 2018. This article is published with open access

Abstract
Copy number alterations (CNAs) are crucial for colorectal cancer (CRC) development. In this study, DEAD box polypeptide 27 (DDX27) was identified to be highly amplified in both TCGA CRC (474/615) and primary CRC (47/103), which was positively correlated with its mRNA overexpression. High DDX27 mRNA (N = 199) and protein expression (N = 260) predicted poor survival in CRC patients. Ectopic expression of DDX27 increased CRC cells proliferation, migration and invasion, but suppressed apoptosis. Conversely, silencing of DDX27 exerted opposite effects in vitro and significantly inhibited murine xenograft tumor growth and lung metastasis in vivo. Up-regulation of DDX27 enhanced and prolonged TNF-α-mediated NF-κB signaling. Nucleophosmin (NPM1) was identified as a binding partner of DDX27. DDX27 increased nuclear NPM1 and NF-κB-p65 interaction to enhance DNA binding activity of NF-κB. Silencing NPM1 abrogated DDX27-activating NF-κB signaling and its tumor-promoting function. Together, DDX27 is overexpressed and plays a pivotal oncogenic role in CRC.

Introduction
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide, accounting for 1.4 million new cases and 0.7 million deaths in 2012 [1]. Emerging evidence indicates that CRC is a heterogeneous disease, arising through accumulation of genetic and epigenetic alterations with three major molecular pathways involved: chromosomal instability (CIN) (50–60%), microsatellite instability and the CpG island methylator phenotype [2]. CIN is a hallmark of CRC, resulting in copy number alterations (CNAs) [3]. CNAs are somatic changes of chromosome structure that lead to gain or loss in copies of DNA sections ranging in size from kilobases to megabases [4]. The stepwise accumulation of CNAs confers growth advantage and metastatic competence on tumor cells, thus playing a crucial role in CRC initiation and progression [5]. DNA copy number gain frequently activates oncogenes [6, 7], whereas tumor suppressors are often found in deleted genomic segments [8, 9]. Recent studies have suggested that genes with CNAs are potential biomarkers and/or therapeutic targets for CRC [5]. Thus, it is of great importance to identify gains or losses of specific genes that contribute to CRC development.
By analyzing CRC genomic data from The Cancer Genome Atlas (TCGA) [10], we demonstrated for the first time the frequent gain of copy number of DEAD-box helicase 27 (DDX27) in CRC. DDX27 belongs to the DEAD box nucleic acid helicase family, which is characterized by a conserved “DEAD-box” sequence motif [11].
DEAD box proteins are highly multifunctional with causative role in carcinogenesis [12]. DDX1 is a positive regulator of cyclin-D2 and indispensable for testicular tumorigenesis [13]. DDX3 promotes breast tumorigenesis through inducing epithelial-mesenchymal-like transition, increasing cell motility and invasion [14]. DDX5 and DDX17 contribute to CRC progression by activating β-catenin signaling in colon cancer [15]. Nevertheless, the function of DDX27 remains largely uncharacterized, especially in CRC. In this study, we investigated its functional significance, molecular mechanism and clinical implication.

Results

DDX27 is frequently amplified in CRC

To identify novel genes with CNAs that are associated with CRC, we comprehensively examined gene-level frequency of copy number gain and loss in 615 human CRC samples from TCGA [10]. Among 24776 genes, DDX27 was identified as one of top ranked genes with the highest frequency of copy number gain (77.1%, 474/615; Fig. 1a and Table S1). On the other hand, analyses of exome sequencing data from TCGA-CRC samples revealed that DDX27 was only mutated in 2.7% of CRC (6/223), of which two were frameshift deletions and the other four were missense mutations (Table S2). To verify the amplification of DDX27 in CRC, we evaluated DDX27 copy number in an independent cohort using TaqMan copy number assay. Consistent with TCGA data, high frequency of DDX27 copy number gain (≥2 copies) was observed (45.6%, 47/103; Fig. 1b).

DNA copy number gain contributes to DDX27 overexpression in CRC

We examined the correlation between DDX27 copy number and mRNA expression. In both Beijing cohort and TCGA cohort, CRC tissues harboring DDX27 amplification exhibited significantly higher mRNA expression as compared to those harboring wild-type DDX27 (without CNA) (both \(P<0.001\); Figs. 1c, d). In Beijing cohort, higher DDX27 protein expression in CRC tissues harboring DDX27 amplification was also observed (\(P<0.05\); Fig. 1c). Furthermore, DDX27 mRNA expression was positively correlated with DNA copy number value in CRC samples of these two cohorts (both \(P<0.001\); Figs. 1c, d). Therefore, gain of copy number is likely a major mechanism that contributes to the up-regulation of DDX27 in CRC.

We next assessed DDX27 expression among various human cancers. Analyses of TCGA gene expression profiling showed significant up-regulation of DDX27 in tumors as compared to adjacent normal tissues in most of human cancer types, especially in CRC (Fig. S1A and Table S3). Overexpression of DDX27 at mRNA and protein level was validated in 151 and 6 pairs of primary CRC as compared to adjacent normal tissues, respectively (\(P<0.001\); Fig. 1e). In keeping with this, immunohistochemical analysis of 278 CRC and 252 adjacent normal tissues confirmed its overexpression at protein level (\(P<0.001\); Fig. 1h).

High DDX27 expression predicts adverse prognosis in CRC patients

Clinical implication of DDX27 in CRC was investigated. In the Beijing cohort, Kaplan–Meier curves revealed that higher DDX27 mRNA expression (optimal cutoff value was determined by the Cutoff Finder tool) was significantly associated with worse relapse-free survival in patients with CRC \((N=199, P<0.05\); Fig. 1f). By multivariate Cox regression analysis, high DDX27 expression was found to be an independent prognostic factor that predicted shorter relapse-free survival \((P<0.05; \text{hazard ratio}: 2.667; 95\% \text{ CI}, 1.116–6.374; \text{Table S6})\). In Beijing cohort, DDX27 expression was independent of age, sex and TNM classification, but was found to be associated with tumor site.
Lower DDX27 expression was found in colon cancer than in rectal cancer ($P < 0.001$; Fig. 1g), an observation verified in TCGA cohort ($P < 0.001$; Fig. S1B). Nevertheless, expression of DDX27 in both colon and rectal cancer was significantly higher than in adjacent normal tissues (both $P < 0.001$; Fig. S1A). We
stratified the cohort according to tumor site and DDX27 expression. This analysis showed that within colon cancer, patients whose tumor exhibited high DDX27 expression had a shorter survival (<0.05; Fig. 1g). In contrast, there was no statistically significant difference for the survival of patients with rectal cancer between DDX27-high and -low groups (Fig. 1g). Consistent result was obtained in TCGA cohort, in which higher expression of DDX27 predicted poor recurrence-free survival in patients with colon cancer (P < 0.01; Fig. S1C). DDX27 expression in primary colon cancer was an independent prognostic marker for survival in both Beijing cohort (<0.05; hazard ratio: 3.362; 95% CI, 1.157 to 9.771; Table S7 and S8) and TCGA cohort (P < 0.05; hazard ratio: 7.345; 95% CI, 1.014 to 53.203; Table S7 and S8) and TCGA cohort (P < 0.05; hazard ratio: 3.362; 95% CI, 1.157 to 9.771; Table S7 and S8). Prognostic value of DDX27 in primary colon cancer was further validated in a third cohort. Our result demonstrated that higher staining density of DDX27 (score ≥8) (Fig. S1D) in primary colon cancer tissues predicted poor overall survival for patients with early stage (I and II) colon cancer in Shanghai cohort (N = 260, P < 0.05; Fig. I1), although this association is not significant by multivariate analysis (P = 0.080; hazard ratio: 1.389; 95% CI, 0.962–2.005; Table S11). Moreover, high DDX27 staining predicted poor overall survival for patients with early stage (I and II) colon cancer in Shanghai cohort, as evidenced by Kaplan-Meier survival analysis (P < 0.05, Fig. S1E) and multivariate analysis (P < 0.05; hazard ratio: 1.860; 95% CI, 1.064–3.250; Table S12). Taken together, DDX27 overexpression is an adverse prognostic factor for CRC patients. DDX27 is located on chromosome 20q, where frequent DNA copy number occurs and correlates with colorectal carcinogenesis. We also evaluated the association between DDX27 and molecular characteristics of colorectal cancer, as defined by TCGA (CIN, invasive, and microsatellite instability/CpG island methylator phenotype (MSI/CIMP) [10]. DDX27 was indeed over-expressed in CIN as compared to invasive and MSI/CIMP subtype (Fig. S1F).

**DDX27 promotes CRC cell growth and inhibits apoptosis**

We determined the mRNA expression of DDX27 in various colon cancer cell lines by qPCR. DDX27 was readily expressed in all investigated CRC cell lines (DLD-1, LoVo, HT29, HCT-116, SW1116, SW480, SW620), but was weakly expressed in normal human colon epithelial cell line (NCM460) and human normal colon tissue (Fig. 2a). DDX27 mainly localized in the nucleus of CRC cell lines, as indicated by western blot analysis (Fig. 2b). The nuclear localization of DDX27 was further confirmed by immunofluorescence staining (Fig. 2c). To characterize the biological role of DDX27, we overexpressed or silenced DDX27 in HCT116 and SW480 cells with lentiviral vectors carrying DDX27 complementary DNA (cDNA) or DDX27-specific small hairpin RNAs (shDDX27), respectively. Controls were transduced with lentiviral carrying empty vector (EV) or negative control shRNA (shCTL). Ectopic expression or silencing of DDX27 was confirmed by reverse transcription polymerase chain reaction and western blot analysis (Fig. 2d). The up-regulation of DDX27 significantly increased cell viability (P < 0.01) and clonogenicity (P < 0.01) in both HCT116 and SW480 cell lines as compared to controls (Fig. 2e). In contrast, silencing of DDX27 reduced cell proliferation (P < 0.01) and colony formation (P < 0.01) (Fig. 2f). Next, we assessed the effect of DDX27 on cell apoptosis. Our results demonstrated that ectopic expression of DDX27 led to a significant reduction in apoptosis with decreased expression of the active (cleaved) forms of caspase-8, caspase-3 and PARP in both HCT116 and SW480 cells, with and without the presence of staurosporine, an apoptosis inducing drug (Fig. 2g). Conversely, DDX27 depletion sensitized CRC cells to staurosporine treatment as evidenced by increased number of apoptotic cells (P < 0.01) and elevated expression of apoptotic markers (Fig. 2h).

To further investigate the tumourigenic ability of DDX27, SW480-EV and SW480-DDX27 cells were subcutaneously injected into the left and right dorsal flanks of nude mice, respectively. As shown in Fig. 3a, ectopic expression of DDX27 significantly accelerated tumor growth in nude mice (P < 0.01). The mean tumor weight of
DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival...

Fig. 3 DDX27 exerted oncogenic function in subcutaneous CRC xenograft mouse models. a Ectopic expression of DDX27 accelerated growth of SW480 xenografts in nude mice \( (N = 5) \) as compared to controls (left panel). Right panel showed image of mice \( (N = 5) \) with tumors and histogram of xenograft tumor weight. Ectopic expression of DDX27 in tumors from SW480-DDX27 groups was confirmed by Western blot (bottom panel). b Representative images of Ki67-positive proliferating cells. c Knockdown of DDX27 decelerated growth of HCT116 xenografts in nude mice \( (N = 5) \) as compared to controls (left panel). Right panel showed representative images of HCT116 xenograft tumors and histogram of tumor weight. Knockdown of DDX27 in tumors from HCT116-shDDX27 groups was confirmed by Western blot (bottom panel). d Representative images of Ki67-positive (Top panel) and TUNEL-positive cells (Bottom panel). At least 5 fields per slide and 3 slides per animal were counted at 200× magnification. \(* P < 0.05; ** P < 0.01; *** P < 0.001\)
the SW480-DDX27 group was increased as compared with SW480-EV group ($P < 0.05$). Overexpression of DDX27 in tumors was confirmed by western blot. In concordance with these findings, more proliferating cells were detected in SW480-DDX27 xenografts, as indicated by Ki-67 assay ($P < 0.05$; Fig. 3b). On the contrary, DDX27 knockdown markedly reduced size and weight of HCT116 xenografts in nude mice (Fig. 3c). Significantly suppressed cell proliferation concomitant with increased apoptosis were observed in HCT116-shDDX27 xenografts, as decreased expression of mesenchymal markers (Slug and Vimentin) while increased expression of epithelial markers (E-cadherin) as indicated by Western blot analysis. f Representative macroscopic appearances of lung metastasis are shown (tumor nodules were indicated as black arrows in top panel). Representative hematoxylin-eosin stained images of the lungs were shown in the bottom panel. Quantification of lung metastatic lesions in HCT116-shCTL ($N = 6$), HCT116-shDDX27-1 ($N = 7$) and HCT116-shDDX27-2 ($N = 7$) groups. Data was expressed as mean ± S.E.M. Student’s $t$-test was performed. ($* P < 0.05; ** P < 0.01; *** P < 0.001$)
DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival...

A

B

C

D

E

F

HCT116 (nuclear)

EV

DDX27

SW480 (nuclear)

EV

DDX27

TNF-α (h)

0 0.5 1 2 3 5

0 0.5 1 2 3 5

kDa

100

70

p65

Ratio: 1.00 1.75 1.92 2.59 2.02 2.04 1.38 2.36 2.38 2.64 2.52 2.87

lamin A/C

70

Springer Nature
DDX27 enhances and prolongs NF-κB signaling

To gain insights into the molecular mechanisms underlying pro-tumorigenic action of DDX27, we screened several important cancer pathways by luciferase reporter assays, including nuclear factor-κB (NF-κB), Wnt/β-catenin (TOPflash/FOPflash), STAT3 (APRE), p53, p38, p21, TGF-β and STAT5 (LHRE) signaling pathways. Among these signaling pathways, ectopic expression of DDX27 uniquely promoted NF-κB luciferase reporter activity in HCT116 cells (P < 0.05; Fig. 5a). On the other hand, knockdown of DDX27 suppressed NF-κB signaling in both HCT116 and SW480 cells (both P < 0.05; Fig. 5a). In order to confirm whether the oncogenic function of DDX27 depends on NF-κB activation, CRC cells with or without ectopic expression of DDX27 were treated with two different NF-κB specific inhibitors, CAPE [16] and JSH-23 [17]. Treatment with either CAPE or JSH-23 markedly abolished the promoting effect of DDX27 on cell proliferation in HCT116 cells, which was further verified in SW480 cells, suggesting that DDX27 promotes CRC growth through activating NF-κB pathway (Fig. 5b). Consistent results were obtained by BrdU cell proliferation assay (Fig. S2A and S2B). NF-κB is a key regulator involved in tumor initiation, progression and metastasis [18]. Constitutive NF-κB activation is frequently observed in CRC [19, 20]. We next performed NF-κB PCR array, which profiles the expression of 84 key genes related to NF-κB-mediated signal transduction [21], to comprehensively analyze the effect of DDX27 on NF-κB signaling. As shown in Fig. 5c, 19 genes were up-regulated by ectopic expression of DDX27 in HCT116 cells treated with tumor necrosis factor alpha (TNF-α), while only three genes were down-regulated. Among these outlier genes, BIRC3, CCL20, CXCL3, NFKBIA, TNF, and TNFAIP3 are NF-κB target genes which were further validated to be significantly up-regulated by ectopic expression of DDX27 in HCT116 by qPCR (Fig. S2). Consistently, expression of these NF-κB target genes induced by TNF-α was enhanced in SW480 cells overexpressing DDX27 at different time points (Fig. 5d), whilst silencing of DDX27 in HCT116 cells reduced expression of the NF-κB target genes (Fig. 5e). To explore the mechanism by which DDX27 regulates NF-κB signaling, we examined the effect of DDX27 on activation of IκB kinase α (IKKα), degradation of IκBα and nuclear translocation of NF-κB p65. Upon TNF-α treatment for short time, DDX27 increases metastatic ability of CRC cells

We investigated the effect of DDX27 on metastatic ability of CRC cells using in vitro migration and invasion assays, as well as in vivo murine lung metastases model. Ectopic expression of DDX27 significantly promoted cell migration (P < 0.001) and invasive capability (P < 0.01) in HCT116 cells compared to control cells (Fig. 4b). Similar results were obtained in SW480 cells (Figs. 4a, b). Western blot analyses showed that DDX27 regulated the epithelial-mesenchymal transition (EMT) through up-regulation of mesenchymal markers (Slug and Vimentin) and down-regulation of epithelial markers (E-cadherin) (Fig. 4c). In contrast, silencing of DDX27 in HCT116 and SW480 cells significantly reduced cell invasion (Fig. 4d), suppressed mesenchymal markers (Slug and Vimentin) and increased epithelial markers (E-cadherin) (Fig. 4e). Furthermore, demonstrated by Ki-67 and TUNEL assays, respectively (both P < 0.05; Fig. 3d). Collectively, these data imply that DDX27 plays a pivotal oncogenic role in colorectal carcinogenesis through promoting cell proliferation and inhibiting apoptosis.
(≤1 h), phosphorylation of IKKα and p65, and degradation of IκBα in CRC cells with either DDX27 overexpression or silencing were similar to that of control (Fig. S3A-S3D), indicating that regulation of TNF-α-induced NF-κB signaling by DDX27 is independent of IKK. This was consistent with the observation that DDX27 did not interfere with p65 nuclear translocation upon TNF-α treatment at the initial time intervals (≤2 h) (Fig. 5f). Thus, we postulated that DDX27 may function downstream of IKK activation and IκBα degradation in simulating NF-κB signaling. Interestingly, TNF-α treatment over extended periods (3–5 h) resulted in decreased expression of IκBα, and increased nuclear accumulation of p65 specifically in CRC cells overexpressing DDX27 (Fig. 5f and S3E), implying a possible positive autocrine feedback loop between activation of NF-κB and translocation of NF-κB p65.
DDX27 increases the interaction of nucleophosmin (NPM1) and NF-κB p65 to promote p65 DNA binding activity

Recent reports have suggested that members of the DEAD box family generally act as components of multi-protein complexes and their functions are likely to be affected by their interacting partners [12]. To identify candidate proteins interacting with DDX27, we expressed HA-tagged DDX27 fused to N-terminus of biotin ligase BirA in 293T cells, and performed affinity purification mass spectrometry using streptavidin beads (Fig. 6a). Among the biotinylated protein targets identified, NPM1 was the most abundant protein (Fig. 6a). Existence of NPM1 in these biotinylated protein targets was further confirmed using anti-NPM1 antibody (Fig. 6b). On the other hand, NF-κB p65 was not identified (Fig. 6b), implying no direct interaction between DDX27 and p65. NPM1 is frequently overexpressed in cancer and is mainly located in the nucleus [22]. The interaction of DDX27 and NPM1 in the nucleus was demonstrated by endogenous reciprocal co-immunoprecipitation (Co-IP) assay in both HCT116 and SW480 cells (Fig. 6c). However, DDX27 regulated neither expression nor nuclear translocation of NPM1 (Fig. S4A). It is reported that NPM1 is associated with nuclear NF-κB p65 to enhance the DNA binding activity of NF-κB in response to TNF-α stimulation, and that NPM1 and NF-κB are likely to act cooperatively to regulate tumor progression [23]. It is therefore plausible that DDX27 may regulate the interaction of NPM1 and p65 in the nucleus. Proximity ligation assay (PLA) was performed to visualize interactions of NPM1 and p65. As shown in Fig. 6d, TNF-α treatment significantly increased endogenous interaction of NPM1 with p65 in the nucleus (P < 0.001). Moreover, in response to TNF-α stimulation, the number of nuclear PLA dots per cell was significantly increased (−1.5 fold) in HCT116 cells with ectopic expression of DDX27 as compared to controls, indicating that up-regulation of DDX27 significantly enhanced the interaction of NPM1 with p65 in nucleus. Consistent result was obtained by endogenous IP assay in HCT116 and SW480 cells (Fig. 6e). TNF-α did not regulate gene expression (Fig. S4A), nuclear translocation (Fig. S4A), or interaction of DDX7 and NPM1 in CRC cells (Fig. S4B). Consequently, the binding activity of p65 to target gene promoters (BIRC3 and TNF) was found to be significantly enhanced in HCT116 cells overexpressing DDX27 by chromatin immunoprecipitation assay (Fig. 6f). We sought to determine whether NPM1 is critical to the oncogenic effect of DDX27. Knockdown of NPM1 abrogated the tumor-promoting function of DDX27, as indicated by MTT assays, without affecting DDX27 expression (Figs. 7a, b). Moreover, NPM1 knockdown abolished DDX27-mediated NF-κB signaling activation and the expression of NF-κB target genes, as evidenced by luciferase reporter assays and qPCR, respectively (Figs. 7c-e). Collectively, these results suggest that DDX27 promoted the interaction between NPM1 and p65 in the nucleus, thereby increasing the DNA binding activity of p65 and promoting NF-κB signaling (Fig. 7f).

Discussion

In this study, our comprehensive analysis of TCGA-CRC cohort led to the novel identification of DDX27 as a putative oncogene with extremely high frequency of copy number gain in CRC, an observation independently verified in our CRC cohort. DDX27 is located on chromosome 20q13.13. DNA copy number gains of chromosomes 20q are commonly found in CRC and are associated with colorectal carcinogenesis [24]. DNA copy number gain is an important cause that drives aberrant overexpression of oncogenes in cancer. We found that DDX27 expression is significantly up-regulated in human CRC at mRNA level and protein level. DDX27 mRNA overexpression was positively correlated with DNA copy number gain inferring that gain of DNA copy number contributes to DDX27 up-regulation in CRC.

DDX27 belongs to the DEAD box nucleic acid helicase family which shares a conserved “DEAD-box” sequence motif [11]. Here, we reported for the first time that DDX27
Fig. 7 Oncogenic effect of DDX27 is dependent on NPM1-mediated activation of NF-κB signaling. a and b Transfection with control-siRNA (siCTL) or specific NPM1-siRNA (siNPM1) in the control and DDX27-overexpressing HCT116 (or SW480 cells) revealed that silencing of NPM1 abolished growth advantage conferred by ectopic expression of DDX27. The cell lysates were blotted with indicated antibody. c and d HCT116 or SW480 cells were treated with 50 ng/ml TNF-α for indicated time. Silencing of NPM1 abolished DDX27-enhanced activation of NF-κB luciferase activity. e HCT116 cells were treated with 50 ng/ml TNF-α for 3 h. The mRNA expression of NF-κB target genes (BIRC3, CXCL3, TNF, and TNFAIP3) were measured by qPCR. f Proposed mechanistic scheme of DDX27. DDX27 directly interacts with NPM1 and promotes its interaction with p65 in the nucleus, hence increased the binding activity of p65 to promoters of NF-κB target genes and enhanced the transcription. DDX27 likely mediates a positive autocrine feedback on NF-κB. Enhanced NF-κB signaling will increase cell proliferation, inhibit apoptosis and promote metastasis for colorectal tumorigenesis. (*P < 0.05; **P < 0.01; ***P < 0.001)
exerted oncogenic role in CRC. DDX27 promoted cell proliferation in CRC cells, an effect that primarily involves suppression of apoptosis as exemplified by the inhibition of caspase cascade. In accordance with in vitro data, DDX27 promoted tumor growth in mouse xenograft models; whilst its knockdown markedly suppressed xenograft growth. Apart from promoting CRC cell growth, DDX27 also regulated metastatic ability by promoting cell migration and invasion in vitro and lung metastasis in vivo. DDX27 positively regulated EMT in CRC cells through up-regulation of Vimentin and Slug, while simultaneously down-regulating E-cadherin expression. Vimentin and Slug are mesenchymal-related proteins that promote migratory and invasive properties of carcinoma cells [25, 26]. Meanwhile, E-cadherin loss is associated with increased cell motility [27]. Collectively, these results indicate that DDX27 exerts oncogenic properties in colorectal carcinogenesis via promoting cell proliferation, inhibiting apoptosis and increasing metastatic abilities. In agreement with our results, recent studies have suggested that several DEAD box proteins have multifunctional roles in biological processes associated with tumorigenesis [13–15]. Among them, DDX1 is frequently co-amplified with N-myc in several types of cancers [28, 29] and plays a crucial role in testicular tumorigenesis [13]. Hence, the frequent gain of copy number of DDX27 in CRC, together with its remarkable oncogenic effect in CRC cells in vitro and in vivo suggests that DDX27 play an important role in triggering CRC initiation and progression.

We examined the molecular mechanism of DDX27 acting as an oncogenic factor in CRC and identified NF-κB pathway as the major target of DDX27 in CRC. NF-κB transcription factor family regulates a mass of genes widely involved in inflammation, angiogenesis, cell proliferation, and metastasis [18]. Constitutive activation of NF-κB pathway is commonly observed in CRC, leading to tumor initiation, invasion and drug resistance [19, 20]. NF-κB activity is induced by various stimuli such as reactive oxygen species, TNF-α, interleukin 1β, and lipopolysaccharides [18]. Upon stimulation, IKK catalyzes phosphorylation and degradation of IκBα. Degradation of IκBα contributes to the release of NF-κB and allows its localization in the nucleus to initiate gene transcription [30]. DDX27 confers NF-κB-mediated growth advantage to CRC cells, which can be abolished by NF-κB specific inhibitors. DDX27 potentiated a prolonged NF-κB response without affecting its initial activation upon TNF-α simulation, implying that it functions downstream of IKK activation and IκBα degradation. DDX27 likely mediates a positive autocrine feedback on NF-κB, leading to enhanced accumulation of p65 in the nucleus after extended TNF-α simulation for 3 h. As a consequence, DDX27 substantially enhanced the expression of NF-κB target genes (BIRC3, CCL20, CXCL3, NFKBIA, TNF, and TNFAIP3) induced by TNF-α. NF-κB target genes are documented to play diverse roles in promoting cell survival and metastasis. BIRC3 (c-IAP2) has been shown to exert positive feedback control on NF-κB via targeting IkBα for degradation and facilitate cell survival by suppressing caspase-8 activation [31–33]. CCL20 and CXCL8 co-expression was shown to be negatively correlated with E-cadherin expression and they cooperatively promote cell metastasis via inducing EMT [34]. On the other hand, exogenous CXCL3 enhanced migration of prostate cancer cells [35]. In this connection, DDX27 may promote tumor survival and EMT via activation of NF-κB. In line with our findings, DDX1 acted as a co-activator of NF-κB to enhance NF-κB-mediated transcription [36]. DDX5 promoted cancer cell viability via direct regulation of NF-κB p50 [37]. Collectively, our work unveiled a novel DEAD Box protein that promotes NF-κB signaling in cancer.

Emerging evidence indicate that DDX proteins regulate signaling pathways as part of multi-protein complexes. Here, we established proximity-dependent biotinylation system [38] and identified NPM1 as the interacting protein of DDX27, which was independently verified by endogenous Co-IP. NPM1 was reported to interact with NF-κB in the nucleus to stimulate the binding of NF-κB to target gene promoters in response to TNF [23]. Accordingly, ectopic expression of DDX27 in CRC cells significantly increased the interaction of NPM1 and p65 upon TNF-α treatment, following by increased binding of NF-κB to promoters of NF-κB target genes. Moreover, NPM1 knockdown abrogated DDX27-mediated NF-κB signaling and CRC cell growth. Hence, DDX27- NPM1- NF-κB forms a functional axis that cooperatively regulates tumor progression.

Finally, the clinical implication of DDX27 was assessed in three independent CRC cohorts, which demonstrated that high expression of DDX27 predicts adverse prognosis in CRC patients, consistent with its putative pro-tumorigenic role in CRC. It is worth noting that prognostic significance of DDX27 might be contributed by the CIN phenotype considering that DDX27 is located on chromosome 20q, where frequent DNA copy number occurs in CRC. It will be of interest if DDX27 may serve as a surrogate marker for CIN in future studies.

In summary, we demonstrated for the first time that DDX27 copy number gain is a common event in CRC which leads to DDX27 overexpression. DDX27 is a novel oncogene involved in colorectal carcinogenesis through increasing cell proliferation, inhibiting apoptosis and promoting metastasis. The oncogenic function of DDX27 was mediated by promoting NF-κB signaling through direct interaction with NPM1. High DDX27 predicts poor prognosis for CRC patients.
Materials and methods

Human CRC samples

Three cohorts of CRC patients were included. For TCGA cohort, CNA and mRNA expression data across 24776 genes of 615 CRC samples were acquired from UCSC Cancer Browser (https://genome-cancer.ucsc.edu/). Surgically excised CRC tissues and surrounding non-tumor tissues were obtained from 199 patients (199 CRC and 151 adjacent normal tissues) with CRC from the Beijing University Cancer Hospital (Beijing cohort) and 278 patients (278 CRC and 252 adjacent normal tissues) with colon cancer from Ren Ji Hospital (Shanghai cohort). The clinicopathological features of patients were shown in Table S4 and S5. Informed consent was provided and patients were regularly followed up. In Beijing cohort, DNA and RNA were isolated from the same CRC tissues of 103 randomly selected patients. In Shanghai cohort, 18 patients were excluded from survival analysis because of incomplete follow-up information. Relapse-free survival and overall survival information were available for Beijing and Shanghai cohort, respectively. This study was approved by the ethics committee of the Chinese University of Hong Kong, Beijing University Cancer Hospital and Ren Ji Hospital.

Tissue microarray assay

Tissue microarrays were stained with DDX27 antibody (Sigma-Aldrich, St. Louis, MO, USA) according to the procedure mentioned previously [39]. The positive percentage was scored as follows: 0, no positive staining; 1, in between 1 and 25% cells; 2, in between 26 and 50% cells; 3, in between 51 and 75% cells; 4, in more than 75% cells. The staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3, high intensity. The immunoreactive score in cytoplasm and nucleus was calculated as staining intensity score x percentage of DDX27-positive cells. The staining score of DDX27 was determined as sum of cytoplasmic score plus nucleic score. The results were scored independently by two pathologists.

Western blot analysis and endogenous immunoprecipitation

Western blot analysis was performed as previously described [40]. The primary antibodies used were NPM1 (Abcam, Cambridge, UK); Caspase 8, Cleaved Caspase 8, Caspase 3, Cleaved Caspase 3, PARP, Cleaved PARP, E-Cadherin (4A2), Slug, IKBa, phosho NF-κB p65(Ser536), NF-κB p65 (D14E12), Phosho-IKKα/β (Ser176/180), IKKα, alpha Tubulin, LaminA/C (Cell Signaling Technology, Danvers, MA, USA); Vimentin (ImmunoWay Biotechnology Company, TX USA); β-actin (Santa Cruz Biotechnology); DDX27 (Sigma-Aldrich, St. Louis, MO, USA). For endogenous immunoprecipitation, immune complexes were precipitated by anti-DDX27, anti-NPM1 or anti-p65 and analyzed by western blot.

BioID proximity-dependent biotinylation

The experiment was performed following the protocol provided by Kyle J. Roux [38]. DDX27 cDNA was fused into pcDNA3.1 MCS-BirA(R118G)-HA (addgene, Cambridge, MA, USA) and 293T cells were transfected with pcDNA3.1-DDX27-BirA-HA or empty vector. 48 h after transfection, 50 μM biotin was added to cells for 24 h. After washed with PBS, cells were lysed in RIPA buffer (25 mM Tris HCl, 150 mM NaCl, 1.0% NP-40, 1.0 mM EDTA and 5% Glycerol) supplemented with with 1×complete protease inhibitor (Roche Applied Sciences). The biotinylated proteins were purified using Dynabeads® Streptavidin (Thermo Fisher Scientific, Waltham, MA, USA) and eluted in SDS-PAGE loading buffer. Eluted proteins were fractionated by SDS-PAGE and visualized by silver staining. Candidate targets were excised from gels and subjected to in-gel digestion and matrix-assisted laser desorption/ionization time-of-flight/ time-of-flight (MALDI-TOF/TOF) mass spectrometry.

Statistical analysis

All results were expressed as mean ± SD unless otherwise indicated. To compare the difference between two groups, Mann-Whitney U-test, Wilcoxon matched-pairs test and Student’s t-test were performed. The difference between growth rates was determined by ANOVA with repeated-measures analysis of variances. The correlation between DDX27 copy number and mRNA expression was analyzed using Spearman rank correlation. The Pearson chi-square test or Fisher’s exact test was used for analysis of the associations between patient clinicopathological characteristics and DDX27 expression. Kaplan-Meier analysis and log-rank test were performed to evaluate the association between DDX27 expression and patient survival. Cutoff value of DDX27 in Beijing or TCGA cohorts was analyzed by survival significance analysis using the tool Cutoff Finder (http://molpath.charite.de/cutoff/) [41]. COX proportion hazard regression model was performed to assess the prognostic value of DDX27 expression. All statistical tests were performed using Graphpad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) or SPSS, version 20.0 (SPSS Inc, Chicago, IL), and a two-tailed P-value of 0.05 was considered statistically significant.
Acknowledgements This work was supported by RGC-GRF Hong Kong (766613, 14106415, 14112116, 14163817), Science and Technology Program Grant, Shenzhen (JCYJ2017041316531462), HMRF Hong Kong (03140856), The National Key Technology R&D Program (2014BA09B05), Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute and CUHK direct grant to Jun Yu, and a grant from the National Natural Science Foundation of China (81372232).

Funding This project was supported by CUHK-SJTU Joint Research Collaboration Fund (Jun Yu and Jing-Yuan Fang), RGC-GRF Hong Kong (766613, 14106415, 973 Program China (2013CB531401), Natural Science Foundation of China (NSFC) (81201963, 81372600), Shenzhen Municipal Science and Technology R & D fund (JCYJ2012061915712650) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. CUHK direct grant to FKL Chan.

Author contributions HRC, JTT, DBL, and TL performed the experiments; HRC, JTT, and CCW analyzed the data; JTT, JYF, XHW, and JFJ provided the samples; HRC and JTT wrote the paper; JY, CCW, JYF, and JJS commented on the study and revised the paper; JY designed, supervised the study and wrote the paper.

Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. 2015;65:87–108.
2. Issa JP. Colon cancer: it’s CIN or CIMP. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2013;14:5939–40.
3. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer. 2009;48:1002–17.
4. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature. 2006;444:444–54.
5. Wang H, Liang L, Fang JY, Xu J. Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers. Oncogene. 2016;35:2011–9.
6. Sillars-Hardebol AH, Carvalho B, Belien JA, de Wit M, Delis-van Diemen PM, Tijssen M et al. BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain. J Pathol. 2012;226:442–50.
7. Flora M, Piana S, Bassano C, Bisagni A, De Marco L, Ciarrocchi A, et al. Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. Cancer Genet. 2012;205:630–5.
8. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al. Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell. 1996;87:175–85.
9. Pouloiganis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA. 2010;107:15145–50.
10. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.
11. Mallam AL, Del Campo M, Gilman B, Sidote DJ, Lambowitz AM. Structural basis for RNA-duplex recognition and unwinding by the DEAD-box helicase Msx116p. Nature. 2012;490:121–5.
12. Fuller-Pace FV. DEAD box RNA helicase functions in cancer. RNA Biol. 2013;10:121–32.
13. Tanaka K, Okamoto S, Ishikawa Y, Tamura H, Hara T. DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene. 2009;28:2142–51.
14. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P Jr, et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008;27:3912–22.
15. Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res. 2007;67:7572–8.
16. Natarajan K, Singh S, Burke TR Jr., Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA. 1996;93:9090–5.
17. Kumar A, Negi G, Sharma SS. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011;13:750–8.
18. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.
19. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res. 2009;15:2248–55.
20. Lind DS, Hochwald SN, Malaty J, Rekkes S, Hebig P, Mishra G, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001;130:363–9.
21. Fiune G, Vecchio E, De Laurentiis A, Trimbolesi F, Palmieri C, Pisano A, et al. Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65. Nucleic Acids Res. 2012;40:3548–62.
22. Lim MJ, Wang XW. Nucleophosmin and human cancer. Cancer Detect Prev. 2006;30:481–90.
23. Lin J, Kato M, Nagata K, Okuwaki M. Efficient DNA binding of NF-kappaB requires the chaperone-like function of NPM1. Nucleic Acids Res. 2017;45:3707–23.
24. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression, Gut. 2009;58:79–89.
25. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30:1436–48.
26. Luanpitpong S, Li J, Manke A, Brundage K, Ellis E, McLaughlin SL, et al. SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma. Oncogene. 2016;35:2824–33.
27. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
28. Godbout R, Squire J. Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc Natl Acad Sci USA. 1993;90:7578–82.
29. George RE, Kenyon RM, McGuckin AG, Malcolm AJ, Pearson AD, Lunec J. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children’s Cancer Study Group. Oncogene. 1996;12:1583–7.
30. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034.
31. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997;94:10057–62.
32. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA. 2008;105:17778–83.
33. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–3.
34. Cheng XS, Li YF, Tan J, Sun B, Xiao YC, Fang XB, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 2014;348:77–87.
35. Gui SL, Teng LC, Wang SQ, Liu S, Lin YL, Zhao XL, et al. Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer. Int Urol Nephrol. 2016;48:701–9.
36. Ishaq M, Ma L, Wu X, Mu Y, Pan J, Hu J, et al. The DEAD-box RNA helicase DDX1 interacts with RelA and enhances nuclear factor kappaB-mediated transcription. J Cell Biochem. 2009;106:296–305.
37. Wang R, Jiao Z, Li R, Yue H, Chen L. p68 RNA helicase promotes glioma cell proliferation in vitro and in vivo via direct regulation of NF-kappaB transcription factor p50. Neuro-Oncol. 2012;14:1116–24.
38. Roux KJ, Kim DI, Raida M, Burke B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J Cell Biol. 2012;196:801–10.
39. Qian Y, Wong CC, Xu J, Chen H, Zhang Y, Kang W, et al. Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation. Cancer Res. 2017;77:1968–82.
40. Chen H, Cai W, Chu ESH, Tang J, Wong CC, Wong SH, et al. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene. 2017;36:4415–26.
41. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PloS ONE. 2012;7:e51862.